







an Open Access Journal by MDPI

Treatment of Dystonia with Botulinum Toxins

Guest Editors:

Prof. David Charles

Vanderbilt University Medical Center, 1161 21st Avenue South, Suite A-1106 MCN, Nashville, TN 37232, USA

Prof. Peter Hedera

Vanderbilt University Medical Center, 1161 21st Avenue South, Suite A-1106 MCN, Nashville, TN 37232, USA

Deadline for manuscript submissions:

closed (28 February 2020)

Message from the Guest Editors

Dear Colleagues,

The treatment of focal dystonia has been revolutionized by botulinum toxins. First approved in 1989 by the US Food and Drug Administration, botulinum toxin injection is now the worldwide mainstay therapy for this often painful and disabling condition. There are several safe and effective botulinum toxins, and more are under development.

This Special Issue of *Toxins* focuses on treatment of the different focal dystonias and provides an overview of available botulinum products and relevant practice guidelines. Included in this Special Issue are in-depth discussions of the treatment of cervical dystonia, blepharospasm, oromandibular dystonia, task specific dystonia, and other limb dystonias.

Prof. David Charles Prof. Peter Hedera *Guest Editors*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Jay Fox
Department of Microbiology,
University of Virginia,
Charlottesville, VA. USA

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peerreviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Contact Us